Celyad Oncology SA
CLYYF
$0.65
-$0.03-4.41%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 193.91% | 199.05% | -68.62% | -67.80% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 193.91% | 199.05% | -68.62% | -67.80% | -- |
| Cost of Revenue | -88.15% | -88.24% | -79.92% | -79.24% | -- |
| Gross Profit | 406.18% | 416.11% | -- | -- | -- |
| SG&A Expenses | -44.04% | -42.91% | -53.14% | -52.03% | -36.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -215.07% | -222.13% | 81.50% | 81.07% | 97.25% |
| Total Operating Expenses | -38.82% | -37.58% | -36.96% | -35.46% | -50.76% |
| Operating Income | 41.67% | 40.50% | 36.67% | 35.16% | 51.36% |
| Income Before Tax | 42.31% | 41.15% | 19.52% | 17.61% | 81.25% |
| Income Tax Expenses | -- | -- | -- | -- | -202.11% |
| Earnings from Continuing Operations | 41.53% | 40.36% | 19.52% | 17.61% | 81.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 41.53% | 40.36% | 19.52% | 17.61% | 81.54% |
| EBIT | 41.67% | 40.50% | 36.67% | 35.16% | 51.36% |
| EBITDA | 42.23% | 42.07% | 36.10% | 34.58% | 52.11% |
| EPS Basic | 59.23% | 58.45% | 57.30% | 55.07% | 85.55% |
| Normalized Basic EPS | 59.86% | 58.87% | 66.80% | 65.08% | 61.57% |
| EPS Diluted | 59.23% | 58.45% | 57.30% | 55.07% | 85.55% |
| Normalized Diluted EPS | 59.86% | 58.87% | 66.80% | 65.08% | 61.57% |
| Average Basic Shares Outstanding | 43.60% | 43.60% | 88.31% | 83.36% | 27.69% |
| Average Diluted Shares Outstanding | 43.60% | 43.60% | 88.31% | 83.36% | 27.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |